| US20060210604A1 | 2006-09-21 | |||
| US20100247606A1 | 2010-09-30 | |||
| US20110104206A1 | 2011-05-05 | |||
| US20110086847A1 | 2011-04-14 |
| CLAIMS 1. An ointment or solution used for treating ptosis and for cosmetic applications, the ointment or solution comprising: a carrier; and one or more of travoprost, dorzolamide hydrochloride, timolol maleate, unoprostone, latanoprost, and bimatoprost. |
CROSS-REFERENCE TO RELATED APPLICATION .
This application claims the benefit of Provisional Application No. 61/515,815, filed August 5, 2011.
TECHNICAL FIELD
The present invention is related to eyelid-related ailments and conditions and, in particular, to treatment of ptosis and other eyelid-related conditions as well as to cosmetic applications to enhance eyelid appearance.
BACKGROUND
Drooping eyelids, a condition referred to as "ptosis," is an often age- related condition that can also be caused by diseases and injuries or by congenital defects, can lead to an undesirable appearance as well as restricted vision. Often, an individual may not have ptosis, but may nonetheless desire, for appearance and cosmetic reasons, for his or her eyelids to appear to open more fully to enhance facial appearance. Currently, surgery is most commonly employed to treat ptosis and to cosmetically enhance eyelid appearance.
SUMMARY
Various embodiments of the present invention are directed topical treatments that improve facial appearance by causing eyelids to naturally open more widely, or be more fully raised, as well as to treatment of ptosis and other eyelid- related conditions.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the structural formula for travoprost.
Figure 2 shows the structural formula for dorzolamide hydrochloride. Figure 3 shows the structural formula for timolol maleate. Figure 4 shows the structural formula for unoprostone.
Figure 5 shows the structural formula for latanoprost.
Figure 6 shows the structural formula for bimatoprost. DETAILED DESCRIPTION
Many medications are currently used to treat glaucoma and ocular hypertension. These include: (1) Travatn®, which contains travoprost, propan-2-yl 7- [3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-b ut-l-enyl3- cyclopentyl]hept-5-enoate, a synthetic prostaglandin F analogue, the structural formula for which is shown in Figure 1; (2) Cosopt®, which includes dorzolamide hydrochloride,(4S,6S)-2-ethylamino-4-methyl-5,5-dioxo-5λ 6 ,7dithiabicyclo[4.3.0] nona-8,10-diene-8-sulfonamide, the structural formula for which is shown in Figure 2; (3) timolol maleate, (S)-l-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazo l- 3-yl)oxy]propan-2-ol, the structural formula for which is shown in Figure 3; (4) Rescula®, which includes unoprostone isopropyl, isopropyl (Z)-7-[(lR,2R,3R,5S)- 3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid, the structural formula for which is shown in Figure 4; (5) Xalatan®, which contains latanoprost, isopropyl (Z)- 7-[(lR,2R,3R,5S)-3,5-dihydroxy-2-[(3R)3-hydroxy-5-phenylpent yl]-cyclopentyl] hept-5-enoate. the structural formula for which is shown in Figure 5; and (6) Lumigan®, which contains bimatoprost, 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl- pent-l-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide, the structural formula for which is shown in Figure 6. These compounds are normally suspended or dissolved in sterile, isotonic, buffered aqueous solutions for use as eye drops, and effect lowering of the internal pressure within the eye, or intraocular pressure.
Recently, the current inventor has discovered that travoprost, dorzolamide hydrochloride, timolol maleate, unoprostone, latanoprost, and bimatoprost can be topically applied, alone or in combination, to the eyelids in order to cause the eyelids to retract more completely, thus ameliorating ptosis and/or improving facial appearance. Embodiments of the present invention include ointments and solutions that include one or more of the compounds travoprost, dorzolamide hydrochloride, and timolol maleate, alone or in combination, and/or one or more chemically-related compounds. These ointments and solutions are topically applied to eyelids in order to treat ptosis and/or to improve facial appearance. The ointments and solution may include, in addition to the above-mentioned active ingredients, stabilizers, buffering compounds, salts, carriers, viscosity enhancers, colorants, emollients, emulsifiers, bactericidal and germicidal agents, preservatives, and other ingredients that improve shelf life, application, consistency, and compatibility with topical application, among other things.